A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.
A PtIV prodrug (PDMA) exhibits great potential for the therapy of metastatic triple-negative breast cancer (TNBC) through a synergistic action of antiangiogensis and antimetastasis.